Top

Published in:

Open Access 01-06-2020 | Leishmania | Review

Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases

Authors: Jorge Alvar, Fabiana Alves, Bruno Bucheton, Louise Burrows, Philippe Büscher, Eugenia Carrillo, Ingrid Felger, Marc P. Hübner, Javier Moreno, Maria-Jesus Pinazo, Isabela Ribeiro, Sergio Sosa-Estani, Sabine Specht, Antoine Tarral, Nathalie Strub Wourgaft, Graeme Bilbe

Published in: Seminars in Immunopathology | Issue 3/2020

Abstract

Progress has been made in the control or elimination of tropical diseases, with a significant reduction of incidence. However, there is a risk of re-emergence if the factors fueling transmission are not dealt with. Although it is essential to understand these underlying factors for each disease, asymptomatic carriers are a common element that may promote resurgence; their impact in terms of proportion in the population and role in transmission needs to be determined. In this paper, we review the current evidence on whether or not to treat asymptomatic carriers given the relevance of their role in the transmission of a specific disease, the efficacy and toxicity of existing drugs, the Public Health interest, and the benefit at an individual level, for example, in Chagas disease, to prevent irreversible organ damage. In the absence of other control tools such as vaccines, there is a need for safer drugs with good risk/benefit profiles in order to change the paradigm so that it addresses the complete infectious process beyond manifest disease to include treatment of non-symptomatic infected persons.

In Ancient Greece, offerings and sacrifices to the gods were performed by the priest at an altar, next to it rich and prominent citizens sat around eating the remaining food; they were called ‘parasites’.

Mansfield J, Olivier M (2011) Immune evasion by parasites. In: Kaufmann S, Rouse B, Sacks D (eds) The immune response to infection. ASM Press Washington DC

Lamb TJ (2012) Immunity to parasitic infection, 1st edn. Wiley-Blackwell

World Health Organization (2015) Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec:33–44

Prata A (2001) Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1:92–100. https://doi.org/10.1016/S1473-3099(01)00065-2 CrossRefPubMed

Villarreal D, Barnabé C, Sereno D, Tibayrenc M (2004) Lack of correlation between in vitro susceptibility to Benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease. Exp Parasitol 108:24–31. https://doi.org/10.1016/j.exppara.2004.07.001 CrossRefPubMed

Nogueira-Paiva NC, De AbreuVieira PM, Oliveri LMR et al (2015) Host-parasite interactions in Chagas disease: genetically unidentical isolates of a single Trypanosoma cruzi strain identified in vitro via LSSP-PCR. PLoS One 10:e0137788. https://doi.org/10.1371/journal.pone.0137788 CrossRefPubMedPubMedCentral

Sánchez-Valdéz FJ, Padilla A, Wang W et al (2018) Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. Elife:e34039. https://doi.org/10.7554/eLife.34039

Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV (2007) Pathogenesis of chronic Chagas heart disease. Circulation 115:1109–1123. https://doi.org/10.1161/CIRCULATIONAHA.106.624296 CrossRefPubMed

Fabbro DL, Danesi E, Olivera V, Codebó MO, Denner S, Heredia C, Streiger M, Sosa-Estani S (2014) Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis 8:e3312. https://doi.org/10.1371/journal.pntd.0003312 CrossRefPubMedPubMedCentral

10.

Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC (2007) Evaluation and treatment of Chagas disease in the United States: a systematic review. J Am Med Assoc 298:2171–2181. https://doi.org/10.1001/jama.298.18.2171 CrossRef

11.

Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, Almeida IC, Alves F, Strub-Wourgaft N, Ribeiro I, E1224 Study Group (2018) Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis 18:419–430. https://doi.org/10.1016/S1473-3099(17)30538-8 CrossRefPubMedPubMedCentral

12.

Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, Pou D, Roure S, Cabezos J, Valerio L, Blanco-Grau A, Sánchez-Montalvá A, Vidal X, Pahissa A (2014) Randomized trial of posaconazole and benznidazole for chronic Chagas’ disease. N Engl J Med 370:1899–1908. https://doi.org/10.1056/NEJMoa1313122 CrossRefPubMed

13.

Pinazo MJ, Guerrero L, Posada E, Rodríguez E, Soy D, Gascon J (2013) Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic Chagas disease. Antimicrob Agents Chemother 57:390–395. https://doi.org/10.1128/AAC.01401-12 CrossRefPubMedPubMedCentral

14.

Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F (2010) Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis 51:e69–e75. https://doi.org/10.1086/656917 CrossRefPubMed

15.

Forsyth CJ, Stigler Granados P, Pacheco GJ, Betancourt JA, Meymandi SK (2019) Current gaps and needs for increasing access to healthcare for people with Chagas disease in the USA. Curr Trop Med Reports 6:13–22. https://doi.org/10.1007/s40475-019-0170-1 CrossRef

16.

Pinazo MJ, Pinto J, Ortiz L, Sánchez J, García W, Saravia R, Cortez MR, Moriana S, Grau E, Lozano D, Gascon J, Torrico F (2017) A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: the Bolivian Chagas Platform. PLoS Negl Trop Dis 11:e0005770. https://doi.org/10.1371/journal.pntd.0005770 CrossRefPubMedPubMedCentral

17.

Pinheiro E, Brum-Soares L, Reis R, Cubides JC (2017) Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America. Rev Soc Bras Med Trop 50:296–300. https://doi.org/10.1590/0037-8682-0433-2016 CrossRefPubMed

18.

Picado A, Angheben A, Marchiol A et al (2017) Development of diagnostics for Chagas disease: where should we put our limited resources? PLoS Negl Trop Dis 5:e0005148. https://doi.org/10.1371/journal.pntd.0005148 CrossRef

19.

Pinazo MJ, Thomas MC, Bustamante J, Almeida IC, Lopez MC, Gascon J (2015) Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. Mem Inst Oswaldo Cruz 110:422–432. https://doi.org/10.1590/0074-02760140435 CrossRefPubMedPubMedCentral

20.

Drugs for Neglected Diseases initiative (2019) Carta de Santa Cruz. https://www.dndial.org/es/2018/comunicacion-e-informacion/es-noticias-dndi/carta-de-santa-cruz/. Accessed 30 Jul 2019

21.

Jamonneau V, Ilboudo H, Kaboré J, Kaba D, Koffi M, Solano P, Garcia A, Courtin D, Laveissière C, Lingue K, Büscher P, Bucheton B (2012) Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis 6:e1691. https://doi.org/10.1371/journal.pntd.0001691 CrossRefPubMedPubMedCentral

22.

Sudarshi D, Lawrence S, Pickrell WO, Eligar V, Walters R, Quaderi S, Walker A, Capewell P, Clucas C, Vincent A, Checchi F, MacLeod A, Brown M (2014) Human African Trypanosomiasis presenting at least 29 years after infection—what can this teach us about the pathogenesis and control of this neglected tropical disease? PLoS Negl Trop Dis 8:e3349. https://doi.org/10.1371/journal.pntd.0003349 CrossRefPubMedPubMedCentral

23.

Ilboudo H, Bras-Gonçalves R, Camara M, Flori L, Camara O, Sakande H, Leno M, Petitdidier E, Jamonneau V, Bucheton B (2014) Unravelling human trypanotolerance: IL8 is associated with infection control whereas IL10 and TNFα are associated with subsequent disease development. PLoS Pathog 10:e1004469. https://doi.org/10.1371/journal.ppat.1004469 CrossRefPubMedPubMedCentral

24.

Gineau L, Courtin D, Camara M, Ilboudo H, Jamonneau V, Dias FC, Tokplonou L, Milet J, Mendonça PB, Castelli EC, Camara O, Camara M, Favier B, Rouas-Freiss N, Moreau P, Donadi EA, Bucheton B, Sabbagh A, Garcia A (2016) Human leukocyte antigen-G: a promising prognostic marker of disease progression to improve the control of human African trypanosomiasis. Clin Infect Dis 63:1189–1197. https://doi.org/10.1093/cid/ciw505 CrossRefPubMed

25.

Morbieu C, Rollin G, Saada N et al (2019) Un très mauvais voyage. Confusion in a 45-year-old woman. La Rev Médecine Interne 40:553–556. https://doi.org/10.1016/j.revmed.2019.05.004 CrossRef

26.

Kaboré J, MacLeod A, Jamonneau V et al (2011) Population genetic structure of Guinea Trypanosoma brucei gambiense isolates according to host factors. Infect Genet Evol 11:129–1135. https://doi.org/10.1016/j.meegid.2011.04.011 CrossRef

27.

Genovese G, Friedman DJ, Ross MD et al (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science (80- ) 329:841–845. https://doi.org/10.1126/science.1193032 CrossRef

28.

Cooper A, Ilboudo H, Alibu VP et al (2017) APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. Elife 6:e25461. https://doi.org/10.7554/eLife.25461 CrossRefPubMedPubMedCentral

29.

Kimuda MP, Noyes H, Mulindwa J, Enyaru J, Alibu VP, Sidibe I, Mumba Ngoyi D, Hertz-Fowler C, MacLeod A, Tastan Bishop Ö, Matovu E, TrypanoGEN Research Group as members of The H3Africa Consortium (2018) No evidence for association between APOL1 kidney disease risk alleles and human African trypanosomiasis in two Ugandan populations. PLoS Negl Trop Dis 12:e0006300. https://doi.org/10.1371/journal.pntd.0006300 CrossRefPubMedPubMedCentral

30.

Ofon E, Noyes H, Mulindwa J, Ilboudo H, Simuunza M, Ebo'o V, Njiokou F, Koffi M, Bucheton B, Fogue P, Hertz-Fowler C, MacLeod A, Simo G, TrypanoGEN Research Group, as members of The H3Africa Consortium (2017) A polymorphism in the haptoglobin, haptoglobin related protein locus is associated with risk of human sleeping sickness within Cameroonian populations. PLoS Negl Trop Dis 11:e0005979. https://doi.org/10.1371/journal.pntd.0005979 CrossRefPubMedPubMedCentral

31.

Ofon E, Noyes H, Ebo’o Eyanga V et al (2019) Association between IL1 gene polymorphism and human African trypanosomiasis in populations of sleeping sickness foci of southern Cameroon. PLoS Negl Trop Dis 13:e0007283. https://doi.org/10.1371/journal.pntd.0007283 CrossRefPubMedPubMedCentral

32.

Ahouty B, Koffi M, Ilboudo H, Simo G, Matovu E, Mulindwa J, Hertz-Fowler C, Bucheton B, Sidibé I, Jamonneau V, MacLeod A, Noyes H, N'Guetta SP, TrypanoGEN Research Group as members of The H3Africa Consortium (2017) Candidate genes-based investigation of susceptibility to human African trypanosomiasis in Côte d’Ivoire. PLoS Negl Trop Dis 11:e0005992. https://doi.org/10.1371/journal.pntd.0005992 CrossRefPubMedPubMedCentral

33.

Ahouty B, Koffi M, Courtin D, et al (1029) HLA-G 3’UTR 14-bp insertion is associated with a decreased risk of developing human African trypanosomiasis in the Côte d’Ivoire population. Open J Genet In press

34.

Kaboré JW, Ilboudo H, Noyes H, Camara O, Kaboré J, Camara M, Koffi M, Lejon V, Jamonneau V, MacLeod A, Hertz-Fowler C, Belem AMG, Matovu E, Bucheton B, Sidibe I, TrypanoGEN Research Group as members of The H3Africa Consortium (2017) Candidate gene polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea. PLoS Negl Trop Dis 11:e0005833. https://doi.org/10.1371/journal.pntd.0005833 CrossRefPubMedPubMedCentral

35.

Capewell P, Cren-Travaillé C, Marchesi F et al (2016) The skin is a significant but overlooked anatomical reservoir for vector-borne African trypanosomes. Elife 5:e17716. https://doi.org/10.7554/eLife.17716 CrossRefPubMedPubMedCentral

36.

Rock KS, Torr SJ, Lumbala C, Keeling MJ (2015) Quantitative evaluation of the strategy to eliminate human African trypanosomiasis in the Democratic Republic of Congo. Parasit Vectors 8:532. https://doi.org/10.1186/s13071-015-1131-8 CrossRefPubMedPubMedCentral

37.

Frézil J (1971) Application du xénodiagnostic dans le dépistage de la trypanosomiase à T. gambiense chez des sujets immunologiquement suspect. Bulletin de la Société de Pathologie Exotique. Bull Soc Pathol Exot Filiales 64:871–878PubMed

38.

Bruneel H, Van den Eeckhout A, Molisho D et al (1994) Contrôle de la trypanosomiase a T.b. gambiense. Evaluation d’une stratégie basée sur le traitement des suspects sérologiques par une dose unique de diminazene. Ann Soc Belg Med Trop (1920) 74:203–215

39.

Frézil J-L, Coulm J, Alary J-C (1979) Evolution après traitement des suspects immunologiques de trypanosomiase non confirmés parasitologiquement. Médecine Trop 39:53–56

40.

Buates S, Matlashewski G (2001) General suppression of macrophage gene expression during Leishmania donovani infection. J Immunol 166:3416–3422. https://doi.org/10.4049/jimmunol.166.5.3416 CrossRefPubMed

41.

Chang KP, Reed SG, McGwire BS, Soong L (2003) Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop 85:375–390. https://doi.org/10.1016/S0001-706X(02)00238-3 CrossRefPubMed

42.

Burza S, Croft SL, Boelaert M (2018) Leishmaniasis. Lancet 392:951–970. https://doi.org/10.1016/S0140-6736(18)31204-2 CrossRefPubMed

43.

Singh OP, Hasker E, Sacks D, Boelaert M, Sundar S (2014) Asymptomatic leishmania infection: a new challenge for leishmania control. Clin Infect Dis 58:1424–1429. https://doi.org/10.1093/cid/ciu102 CrossRefPubMedPubMedCentral

44.

Marty P, Izri A, Ozon C, Haas P, Rosenthal E, del Giudice P, Godenir J, Coulibaly E, Gari-Toussaint M, Delaunay P, Ferrua B, Haas H, Pratlong F, le Fichoux Y (2007) A century of leishmaniasis in Alpes-Maritimes, France. Ann Trop Med Parasitol 101:563–574. https://doi.org/10.1179/136485907x229121 CrossRefPubMed

45.

Ibarra-Meneses AV, Carrillo E, Nieto J et al (2019) Prevalence of asymptomatic Leishmania infection and associated risk factors, after an outbreak in the south-western Madrid region, Spain, 2015. Euro Surveill 24. https://doi.org/10.2807/1560-7917.ES.2019.24.22.1800379

46.

Rai M, Sundar S, Gidwani K, Kumar R (2009) Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg 80:345–346. https://doi.org/10.4269/ajtmh.2009.80.345 CrossRefPubMed

47.

Das VNR, Siddiqui NA, Verma RB, Topno RK, Singh D, Das S, Ranjan A, Pandey K, Kumar N, Das P (2011) Asymptomatic infection of visceral leishmaniasis in hyperendemic areas of Vaishali district, Bihar, India: a challenge to kala-azar elimination programmes. Trans R Soc Trop Med Hyg 105:661–666. https://doi.org/10.1016/j.trstmh.2011.08.005 CrossRefPubMed

48.

Chakravarty J, Hasker E, Kansal S, Singh OP, Malaviya P, Singh AK, Chourasia A, Singh T, Sudarshan M, Singh AP, Singh B, Singh RP, Ostyn B, Fakiola M, Picado A, Menten J, Blackwell JM, Wilson ME, Sacks D, Boelaert M, Sundar S (2019) Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: a cohort study. PLoS Negl Trop Dis 13:e0007216. https://doi.org/10.1371/journal.pntd.0007216 CrossRefPubMedPubMedCentral

49.

Costa CHN, Stewart JM, Gomes RBB, Garcez LM, Ramos PK, Bozza M, Satoskar A, Dissanayake S, Santos RS, Silva MR, Shaw JJ, David JR, Maguire JH (2002) Asymptomatic human carriers of Leishmania chagasi. Am J Trop Med Hyg 66:334–337. https://doi.org/10.4269/ajtmh.2002.66.334 CrossRefPubMed

50.

Das S, Matlashewski G, Bhunia GS et al (2014) Asymptomatic Leishmania infections in northern India: a threat for the elimination programme? Trans R Soc Trop Med Hyg 108:679–684. https://doi.org/10.1093/trstmh/tru146 CrossRefPubMed

51.

Hasker E, Kansal S, Malaviya P, Gidwani K, Picado A, Singh RP, Chourasia A, Singh AK, Shankar R, Menten J, Wilson ME, Boelaert M, Sundar S (2013) Latent infection with Leishmania donovani in Highly Endemic Villages in Bihar, India. PLoS Negl Trop Dis 7:e2053. https://doi.org/10.1371/journal.pntd.0002053 CrossRefPubMedPubMedCentral

52.

Hailu A, Gramiccia M, Kager PA (2009) Visceral leishmaniasis in Aba-Roba, south–western Ethiopia: prevalence and incidence of active and subclinical infections. Ann Trop Med Parasitol 103:659–670. https://doi.org/10.1179/000349809x12554106963555 CrossRefPubMed

53.

Sassi A, Louzir H, Ben SA et al (1999) Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia. Clin Exp Immunol 116:127–132. https://doi.org/10.1046/j.1365-2249.1999.00844.x CrossRefPubMedPubMedCentral

54.

Ibarra-Meneses AV, Ghosh P, Hossain F et al (2017) IFN-γ, IL-2, IP-10, and MIG as biomarkers of exposure to Leishmania spp., and of cure in human visceral Leishmaniasis. Front Cell Infect Microbiol 7:200. https://doi.org/10.3389/fcimb.2017.00200 CrossRefPubMedPubMedCentral

55.

Michel G, Pomares C, Ferrua B, Marty P (2011) Importance of worldwide asymptomatic carriers of Leishmania infantum (L. chagasi) in human. Acta Trop 119:69–75. https://doi.org/10.1016/j.actatropica.2011.05.012 CrossRefPubMed

56.

Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Duerr HP (2011) Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis 5:e1405. https://doi.org/10.1371/journal.pntd.0001405 CrossRefPubMedPubMedCentral

57.

Das P, Samuels S, Desjeux P et al (2010) Annual incidence of visceral leishmaniasis in an endemic area of Bihar, India. Tropical Med Int Health 15:4–11. https://doi.org/10.1111/j.1365-3156.2010.02517.x CrossRef

58.

Costa CHN, Gomes RBB, Silva MRB, Garcez LM, Ramos PK, Santos RS, Shaw JJ, David JR, Maguire JH (2000) Competence of the human host as a reservoir for Leishmania chagasi. J Infect Dis 182:997–1000. https://doi.org/10.1086/315795 CrossRefPubMed

59.

García-García JA, Martín-Sánchez J, Gállego M, Rivero-Román A, Camacho A, Riera C, Morillas-Márquez F, Vergara S, Macías J, Pineda JA (2006) Use of noninvasive markers to detect Leishmania infection in asymptomatic human immunodeficiency virus-infected patients. J Clin Microbiol 44:4455–4458. https://doi.org/10.1128/JCM.00921-06 CrossRefPubMedPubMedCentral

60.

Carrillo E, Carrasco-Antón N, López-Medrano F, Salto E, Fernández L, San Martín JV, Alvar J, Aguado JM, Moreno J (2015) Cytokine release assays as tests for exposure to Leishmania, and for confirming cure from leishmaniasis, in solid organ transplant recipients. PLoS Negl Trop Dis 9:e0004179. https://doi.org/10.1371/journal.pntd.0004179 CrossRefPubMedPubMedCentral

61.

Botana L, Ibarra-Meneses AV, Sánchez C, Castro A, San Martin JV, Molina L, Ruiz-Giardin JM, Carrillo E, Moreno J (2019) Asymptomatic immune responders to Leishmania among HIV positive patients. PLoS Negl Trop Dis 13:e0007461. https://doi.org/10.1371/journal.pntd.0007461 CrossRefPubMedPubMedCentral

62.

Molina R, Cafiavate C, Cercenado E et al (1994) Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus. AIDS 8:277–279. https://doi.org/10.1097/00002030-199402000-00024 CrossRefPubMed

63.

Simonsen PE, Onapa AW, Asio SM (2011) Mansonella perstans filariasis in Africa. Acta Trop 120:5109–5120. https://doi.org/10.1016/j.actatropica.2010.01.014 CrossRef

64.

Klion AD, Massougbodji A, Sadeler BC, Ottesen EA, Nutman TB (1991) Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation. J Infect Dis 163:1318–1325. https://doi.org/10.1093/infdis/163.6.1318 CrossRefPubMed

65.

Hoerauf A, Pfarr K, Mand S, Debrah AY, Specht S (2011) Filariasis in Africa-treatment challenges and prospects. Clin Microbiol Infect 17:977–985. https://doi.org/10.1111/j.1469-0691.2011.03586.x CrossRefPubMed

66.

World Health Organization (2017) Guideline: alternative mass drug administration regimens to eliminate lymphatic filariasis

67.

Hoerauf A, Brattig N (2002) Resistance and susceptibility in human onchocerciasis - beyond Th1 vs Th2. Trends Parasitol 18:25–31. https://doi.org/10.1016/S1471-4922(01)02173-0 CrossRefPubMed

68.

Maizels RM, McSorley HJ (2016) Regulation of the host immune system by helminth parasites. J Allergy Clin Immunol 138:666–675. https://doi.org/10.1016/j.jaci.2016.07.007 CrossRefPubMedPubMedCentral

69.

Katawa G, Layland LE, Debrah AY, von Horn C, Batsa L, Kwarteng A, Arriens S, W Taylor D, Specht S, Hoerauf A, Adjobimey T (2015) Hyperreactive onchocerciasis is characterized by a combination of Th17-Th2 immune responses and reduced regulatory T cells. PLoS Negl Trop Dis 9:e3414. https://doi.org/10.1371/journal.pntd.0003414 CrossRefPubMedPubMedCentral

70.

Arndts K, Deininger S, Specht S, Klarmann U, Mand S, Adjobimey T, Debrah AY, Batsa L, Kwarteng A, Epp C, Taylor M, Adjei O, Layland LE, Hoerauf A (2012) Elevated adaptive immune responses are associated with latent infections of Wuchereria bancrofti. PLoS Negl Trop Dis 6:e1611. https://doi.org/10.1371/journal.pntd.0001611 CrossRefPubMedPubMedCentral

71.

Hoerauf A, Satoguina J, Saeftel M, Specht S (2005) Immunomodulation by filarial nematodes. Parasite Immunol 27:417–429. https://doi.org/10.1111/j.1365-3024.2005.00792.x CrossRefPubMed

72.

Berbudi A, Ajendra J, Wardani APF, Hoerauf A, Hübner MP (2016) Parasitic helminths and their beneficial impact on type 1 and type 2 diabetes. Diabetes Metab Res Rev 32:238–250. https://doi.org/10.1002/dmrr.2673 CrossRefPubMed

73.

Hübner MP, Layland LE, Hoerauf A (2013) Helminths and their implication in sepsis - a new branch of their immunomodulatory behaviour? Pathog Dis 69:127–141. https://doi.org/10.1111/2049-632X.12080 CrossRefPubMed

74.

Metenou S, Dembele B, Konate S, Dolo H, Coulibaly YI, Diallo AA, Soumaoro L, Coulibaly ME, Coulibaly SY, Sanogo D, Doumbia SS, Traoré SF, Mahanty S, Klion A, Nutman TB (2011) Filarial infection suppresses malaria-specific multifunctional Th1 and Th17 responses in malaria and filarial coinfections. J Immunol 186:4725–4733. https://doi.org/10.4049/jimmunol.1003778 CrossRefPubMed

75.

Metenou S, Dembélé B, Konate S, Dolo H, Coulibaly SY, Coulibaly YI, Diallo AA, Soumaoro L, Coulibaly ME, Sanogo D, Doumbia SS, Wagner M, Traoré SF, Klion A, Mahanty S, Nutman TB (2009) Patent filarial infection modulates malaria-specific type 1 cytokine responses in an IL-10-dependent manner in a filaria/malaria-coinfected population. J Immunol 183:916–924. https://doi.org/10.4049/jimmunol.0900257 CrossRefPubMed

76.

Dolo H, Coulibaly YI, Dembele B et al (2012) Filariasis attenuates anemia and proinflammatory responses associated with clinical malaria: a matched prospective study in children and young adults. PLoS Negl Trop Dis 6:e1890. https://doi.org/10.1371/journal.pntd.0001890 CrossRefPubMedPubMedCentral

77.

Babu S, Nutman TB (2016) Helminth-tuberculosis co-infection: an immunologic perspective. Trends Immunol 37:597–607. https://doi.org/10.1016/j.it.2016.07.005 CrossRefPubMedPubMedCentral

78.

Chatterjee S, Kolappan C, Subramani R, Gopi PG, Chandrasekaran V, Fay MP, Babu S, Kumaraswami V, Nutman TB (2014) Incidence of active pulmonary tuberculosis in patients with coincident filarial and/or intestinal helminth infections followed longitudinally in South India. PLoS One 9:e94603. https://doi.org/10.1371/journal.pone.0094603 CrossRefPubMedPubMedCentral

79.

Kroidl I, Saathoff E, Maganga L et al (2016) Effect of Wuchereria bancrofti infection on HIV incidence in southwest Tanzania: a prospective cohort study. Lancet 388:1912–1920. https://doi.org/10.1016/S0140-6736(16)31252-1 CrossRefPubMed

80.

Osborne LC, Monticelli LA, Nice TJ et al (2014) Virus-helminth coinfection reveals a microbiota-independent mechanism of immunomodulation. Science (80- ) 345:578–582. https://doi.org/10.1126/science.1256942 CrossRef

81.

Talaat KR, Babu S, Menon P, Kumarasamy N, Sharma J, Arumugam J, Dhakshinamurthy K, Srinivasan R, Poongulali S, Gu W, Fay MP, Swaminathan S, Nutman TB (2015) Treatment of W. bancrofti (Wb) in HIV/Wb coinfections in South India. PLoS Negl Trop Dis 9:e0003622. https://doi.org/10.1371/journal.pntd.0003622 CrossRefPubMedPubMedCentral

82.

Cooper P, Espinel I, Paredes W, Guderian RH, Nutman TB (1998) Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human Onchocerciasis: a possible role for interleukin-10. J Infect Dis 178:1133–1138. https://doi.org/10.1086/515661 CrossRefPubMed

83.

World Health Organization (2018) WHO technical consultation on research requirements to support policy recommendations on highly sensitive point-of-care diagnostics for P. falciparum malaria. In: World Malar. Rep. www.who.int/malaria. Accessed 12 Sept 2019

84.

Björkman A, Shakely D, Ali AS, Morris U, Mkali H, Abbas AK, al-Mafazy AW, Haji KA, Mcha J, Omar R, Cook J, Elfving K, Petzold M, Sachs MC, Aydin-Schmidt B, Drakeley C, Msellem M, Mårtensson A (2019) From high to low malaria transmission in Zanzibar - challenges and opportunities to achieve elimination. BMC Med 17:14. https://doi.org/10.1186/s12916-018-1243-z CrossRefPubMedPubMedCentral

85.

Churcher TS, Bousema T, Walker M, Drakeley C, Schneider P, Ouédraogo AL, Basáñez MG (2013) Predicting mosquito infection from Plasmodium falciparum gametocyte density and estimating the reservoir of infection. Elife 2:e00626. https://doi.org/10.7554/eLife.00626 CrossRefPubMedPubMedCentral

86.

Bousema T, Okell L, Felger I, Drakeley C (2014) Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nat Rev Microbiol 12:833–840. https://doi.org/10.1038/nrmicro3364 CrossRefPubMed

87.

Britton S, Cheng Q, Grigg MJ et al (2016) Sensitive detection of Plasmodium vivax using a high-throughput, colourimetric loop mediated isothermal amplification (HtLAMP) platform: a potential novel tool for malaria elimination. PLoS Negl Trop Dis 10:e0004443. https://doi.org/10.1371/journal.pntd.0004443 CrossRefPubMedPubMedCentral

88.

Hassanpour G, Mohebali M, Zeraati H et al (2017) Asymptomatic malaria and its challenges in the malaria elimination program in Iran: a systematic review. J Arthropod Borne Dis 11:321–330

89.

d’Acremont V, Malila A, Swai N et al (2010) Withholding antimalarials in febrile children who have a negative result for a rapid diagnostic test. Clin Infect Dis 51:506–511. https://doi.org/10.1086/655688 CrossRefPubMed

90.

Senn N, Rarau P, Manong D, Salib M, Siba P, Robinson LJ, Reeder J, Rogerson S, Mueller I, Genton B (2012) Rapid diagnostic test-based management of malaria: an effectiveness study in Papua New Guinean infants with plasmodium falciparum and plasmodium vivax malaria. Clin Infect Dis 54:644–651. https://doi.org/10.1093/cid/cir901 CrossRefPubMed

91.

Hofmann NE, Gruenberg M, Nate E, Ura A, Rodriguez-Rodriguez D, Salib M, Mueller I, Smith TA, Laman M, Robinson LJ, Felger I (2018) Assessment of ultra-sensitive malaria diagnosis versus standard molecular diagnostics for malaria elimination: an in-depth molecular community cross-sectional study. Lancet Infect Dis 18:1108–1116. https://doi.org/10.1016/S1473-3099(18)30411-0 CrossRefPubMed

92.

Okell LC, Ghani AC, Lyons E, Drakeley CJ (2009) Submicroscopic infection in Plasmodium falciparum –endemic populations: a systematic review and meta-analysis. J Infect Dis 200:1509–1517. https://doi.org/10.1086/644781 CrossRefPubMed

93.

Okell LC, Bousema T, Griffin JT et al (2012) Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun 3. https://doi.org/10.1038/ncomms2241

94.

Nguyen TN, von Seidlein L, Nguyen TV et al (2018) The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study. Lancet Infect Dis 18:565–572. https://doi.org/10.1016/S1473-3099(18)30046-X CrossRefPubMedPubMedCentral

95.

Almeida ACG, Kuehn A, Castro AJM, Vitor-Silva S, Figueiredo EFG, Brasil LW, Brito MAM, Sampaio VS, Bassat Q, Felger I, Tadei WP, Monteiro WM, Mueller I, Lacerda MVG (2018) High proportions of asymptomatic and submicroscopic Plasmodium vivax infections in a peri-urban area of low transmission in the Brazilian Amazon. Parasit Vectors 11:194. https://doi.org/10.1186/s13071-018-2787-7 CrossRefPubMedPubMedCentral

96.

Kobayashi T, Kanyangarara M, Laban NM et al (2019) Characteristics of subpatent malaria in a pre-elimination setting in southern Zambia. Am J Trop Med Hyg 100:280–286. https://doi.org/10.4269/ajtmh.18-0399 CrossRefPubMed

97.

Cheng Q, Cunningham J, Gatton ML (2015) Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors. PLoS Negl Trop Dis 9:e3413. https://doi.org/10.1371/journal.pntd.0003413 CrossRefPubMedPubMedCentral

98.

Moreira CM, Abo-Shehada M, Price RN, Drakeley CJ (2015) A systematic review of sub-microscopic Plasmodium vivax infection. Malar J 14:360. https://doi.org/10.1186/s12936-015-0884-z CrossRefPubMedPubMedCentral

99.

Coleman RE, Sattabongkot J, Promstaporm S et al (2006) Comparison of PCR and microscopy for the detection of asymptomatic malaria in a Plasmodium falciparum/vivax endemic area in Thailand. Malar J 5:121. https://doi.org/10.1186/1475-2875-5-121 CrossRefPubMedPubMedCentral

100.

Gruenberg M, Moniz CA, Hofmann NE, Wampfler R, Koepfli C, Mueller I, Monteiro WM, Lacerda M, de Melo GC, Kuehn A, Siqueira AM, Felger I (2018) Plasmodium vivax molecular diagnostics in community surveys: pitfalls and solutions. Malar J 17:55. https://doi.org/10.1186/s12936-018-2201-0 CrossRefPubMedPubMedCentral

101.

Imwong M, Hanchana S, Malleret B, Rénia L, Day NP, Dondorp A, Nosten F, Snounou G, White NJ (2014) High-throughput ultrasensitive molecular techniques for quantifying low-density malaria parasitemias. J Clin Microbiol 52:3303–3309. https://doi.org/10.1128/JCM.01057-14 CrossRefPubMedPubMedCentral

102.

Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I (2015) Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med 12:e1001788. https://doi.org/10.1371/journal.pmed.1001788 CrossRefPubMedPubMedCentral

Title: Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases
Authors: Jorge Alvar
Fabiana Alves
Bruno Bucheton
Louise Burrows
Philippe Büscher
Eugenia Carrillo
Ingrid Felger
Marc P. Hübner
Javier Moreno
Maria-Jesus Pinazo
Isabela Ribeiro
Sergio Sosa-Estani
Sabine Specht
Antoine Tarral
Nathalie Strub Wourgaft
Graeme Bilbe
Publication date: 01-06-2020
Publisher: Springer Berlin Heidelberg
Keywords: Leishmania
Malaria
Leishmania
Published in: Seminars in Immunopathology / Issue 3/2020
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-020-00796-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Introduction: immunopathology of unresolved tropical diseases

Schistosomiasis—from immunopathology to vaccines

Towards new TB vaccines

Leishmaniasis immunopathology—impact on design and use of vaccines, diagnostics and drugs

Correction to: Schistosomiasis—from immunopathology to vaccines

The immunology of other mycobacteria: M. ulcerans, M. leprae

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page